CVRx to present late-breaking REBALANCE Registry real-world Barostim outcomes at HFSA 2026
CVRX•CVRx said late-breaking analyses from the REBALANCE real-world registry are scheduled for Oct. 11 at the HFSA Annual Scientific Meeting, alongside Barostim data from the BENEFIT-HF trial.
1. Meeting presentations
CVRx flagged new clinical evidence for its Barostim heart-failure device ahead of the HFSA Annual Scientific Meeting in October. The REBALANCE Registry results have not yet been presented; the company also highlighted first real-world evidence in HFmrEF, pointing to reduced hospitalization burden in routine commercial use, and said BENEFIT-HF data in an expanded patient population will appear in the meeting’s clinical trial ePoster hub.
